Revised Bid for Monash IVF Likely Compelling for Shareholders -- Market Talk

Dow Jones

Apr 14

0031 GMT - The bar for Monash IVF's board to reject a revised offer from Genesis Capital Investment and Washington H. Soul Pattinson is higher than when it knocked back the consortium's first bid in November, says Morgans. The consortium's new offer is worth A$0.90/share in cash, up from A$0.80/share proposed before. Analyst Emily Porter says Monash IVF is operating in a challenging macro environment. It's facing soft industry cycle volumes, ongoing reputational headwinds from incidents involving embryos and declining net profit. "Against that backdrop, despite a discount to comparable IVF transactions, we think the offer is compelling for shareholders," Morgans says.(david.winning@wsj.com; @dwinningWSJ)

(END) Dow Jones Newswires

April 13, 2026 20:31 ET (00:31 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/2627446275"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2627446275\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2627446275?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-14 08:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2627446275","market":"hk","top_or_hot":-1,"title":"Revised Bid for Monash IVF Likely Compelling for Shareholders -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0031 GMT - The bar for <a href=\"https://laohu8.com/S/MNIVF\">Monash IVF</a>'s board to reject a revised offer from Genesis Capital Investment and <a href=\"https://laohu8.com/S/SOL.AU\">Washington H. Soul Pattinson</a> is higher than when it knocked back the consortium's first bid in November, says Morgans. The consortium's new offer is worth A$0.90/share in cash, up from A$0.80/share proposed before. Analyst Emily Porter says Monash IVF is operating in a challenging macro environment. It's facing soft industry cycle volumes, ongoing reputational headwinds from incidents involving embryos and declining net profit. \"Against that backdrop, despite a discount to comparable IVF transactions, we think the offer is compelling for shareholders,\" Morgans says.(david.winning@wsj.com; @dwinningWSJ) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 13, 2026 20:31 ET (00:31 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Revised Bid for Monash IVF Likely Compelling for Shareholders -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRevised Bid for Monash IVF Likely Compelling for Shareholders -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-04-14 08:31</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0031 GMT - The bar for <a href=\"https://laohu8.com/S/MNIVF\">Monash IVF</a>'s board to reject a revised offer from Genesis Capital Investment and <a href=\"https://laohu8.com/S/SOL.AU\">Washington H. Soul Pattinson</a> is higher than when it knocked back the consortium's first bid in November, says Morgans. The consortium's new offer is worth A$0.90/share in cash, up from A$0.80/share proposed before. Analyst Emily Porter says Monash IVF is operating in a challenging macro environment. It's facing soft industry cycle volumes, ongoing reputational headwinds from incidents involving embryos and declining net profit. \"Against that backdrop, despite a discount to comparable IVF transactions, we think the offer is compelling for shareholders,\" Morgans says.(david.winning@wsj.com; @dwinningWSJ) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 13, 2026 20:31 ET (00:31 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7113","symbol_name":"保健护理机构","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2627446275","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2627446275","pubTimestamp":1776126660,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0031 GMT - The bar for Monash IVF's board to reject a revised offer from Genesis Capital Investment and Washington H. Soul Pattinson is higher than when it knocked back the consortium's first bid in November, says Morgans. The consortium's new offer is worth A$0.90/share in cash, up from A$0.80/share proposed before. Analyst Emily Porter says Monash IVF is operating in a challenging macro environment. It's facing soft industry cycle volumes, ongoing reputational headwinds from incidents involving embryos and declining net profit. \"Against that backdrop, despite a discount to comparable IVF transactions, we think the offer is compelling for shareholders,\" Morgans says.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7113":"保健护理机构","BK4082":"医疗保健设备","BK7508":"医药生物股","MVF.AU":"MONASH IVF GROUP LTD","SOL.AU":"WASHINGTON H. SOUL PATTINSON","BK7083":"煤与消费用燃料","IVF":"INVO Fertility, Inc","BK7105":"多领域控股"},"translate_title":"莫纳什IVF的修订出价可能会吸引股东——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IVF":1.5,"SOL.AU":0.9,"MVF.AU":0.9},"content_text":"0031 GMT - The bar for Monash IVF's board to reject a revised offer from Genesis Capital Investment and Washington H. Soul Pattinson is higher than when it knocked back the consortium's first bid in November, says Morgans. The consortium's new offer is worth A$0.90/share in cash, up from A$0.80/share proposed before. Analyst Emily Porter says Monash IVF is operating in a challenging macro environment. It's facing soft industry cycle volumes, ongoing reputational headwinds from incidents involving embryos and declining net profit. \"Against that backdrop, despite a discount to comparable IVF transactions, we think the offer is compelling for shareholders,\" Morgans says.(david.winning@wsj.com; @dwinningWSJ) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 13, 2026 20:31 ET (00:31 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}